This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Almac Discovery Limited. Active years: 2015-2023.
Company Filing History:
Years Active: 2015-2023
Title: Steven David Shepherd: Innovator in Pharmaceutical Research
Introduction
Steven David Shepherd is a notable inventor based in Craigavon, GB. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target critical biological pathways. With a total of 2 patents, his work has the potential to impact various medical conditions.
Latest Patents
Among his latest patents, Shepherd has developed 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19). These inhibitors are designed to treat conditions such as muscular atrophy, obesity, insulin resistance, and type II diabetes. Additionally, he has created AKT inhibitor compounds for the treatment of cancer. These compounds are aimed at inhibiting the activity of the serine/threonine kinase, AKT, and are intended for use in pharmaceutical compositions for cancer treatment.
Career Highlights
Shepherd is currently associated with Almac Discovery Limited, where he continues to advance his research and innovation in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments for serious health issues.
Collaborations
Some of his notable coworkers include Frank Burkamp and Colin O'Dowd, who contribute to the collaborative environment at Almac Discovery Limited.
Conclusion
Steven David Shepherd's innovative work in pharmaceutical research exemplifies the impact of targeted therapies in modern medicine. His contributions are paving the way for new treatments that address significant health challenges.